Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Net Income (2021 - 2025)

Prime Medicine (PRME) has disclosed Net Income for 5 consecutive years, with -$47.5 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income fell 12.42% year-over-year to -$47.5 million, compared with a TTM value of -$204.8 million through Dec 2025, down 4.57%, and an annual FY2025 reading of -$204.2 million, down 4.25% over the prior year.
  • Net Income was -$47.5 million for Q4 2025 at Prime Medicine, up from -$52.8 million in the prior quarter.
  • Across five years, Net Income topped out at -$10.4 million in Q3 2021 and bottomed at -$65.6 million in Q4 2023.
  • Average Net Income over 5 years is -$44.1 million, with a median of -$46.6 million recorded in 2024.
  • Peak annual rise in Net Income hit 37.54% in 2022, while the deepest fall reached 181.48% in 2022.
  • Year by year, Net Income stood at -$62.9 million in 2021, then soared by 37.54% to -$39.3 million in 2022, then tumbled by 67.1% to -$65.6 million in 2023, then surged by 35.6% to -$42.3 million in 2024, then decreased by 12.42% to -$47.5 million in 2025.
  • Business Quant data shows Net Income for PRME at -$47.5 million in Q4 2025, -$52.8 million in Q3 2025, and -$52.6 million in Q2 2025.